GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncimmune Holdings PLC (LSE:ONC) » Definitions » Net Margin %

Oncimmune Holdings (LSE:ONC) Net Margin % : -92.66% (As of Feb. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Oncimmune Holdings Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Oncimmune Holdings's Net Income for the six months ended in Feb. 2024 was £-1.10 Mil. Oncimmune Holdings's Revenue for the six months ended in Feb. 2024 was £1.19 Mil. Therefore, Oncimmune Holdings's net margin for the quarter that ended in Feb. 2024 was -92.66%.

The historical rank and industry rank for Oncimmune Holdings's Net Margin % or its related term are showing as below:

LSE:ONC' s Net Margin % Range Over the Past 10 Years
Min: -4685.38   Med: -979.29   Max: 581.63
Current: 581.63


LSE:ONC's Net Margin % is ranked better than
98.64% of 1027 companies
in the Biotechnology industry
Industry Median: -151.78 vs LSE:ONC: 581.63

Oncimmune Holdings Net Margin % Historical Data

The historical data trend for Oncimmune Holdings's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncimmune Holdings Net Margin % Chart

Oncimmune Holdings Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 Aug23
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4,685.38 -1,661.89 -134.12 -296.69 356.25

Oncimmune Holdings Semi-Annual Data
May14 Nov14 May15 Nov15 May16 Nov16 May17 Nov17 May18 Nov18 May19 Nov19 May20 Nov20 May21 Nov21 May22 Feb23 Aug23 Feb24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -340.07 -261.77 -360.85 29,142.86 -92.66

Competitive Comparison of Oncimmune Holdings's Net Margin %

For the Biotechnology subindustry, Oncimmune Holdings's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncimmune Holdings's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncimmune Holdings's Net Margin % distribution charts can be found below:

* The bar in red indicates where Oncimmune Holdings's Net Margin % falls into.



Oncimmune Holdings Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Oncimmune Holdings's Net Margin for the fiscal year that ended in Aug. 2023 is calculated as

Net Margin=Net Income (A: Aug. 2023 )/Revenue (A: Aug. 2023 )
=4.104/1.152
=356.25 %

Oncimmune Holdings's Net Margin for the quarter that ended in Feb. 2024 is calculated as

Net Margin=Net Income (Q: Feb. 2024 )/Revenue (Q: Feb. 2024 )
=-1.099/1.186
=-92.66 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oncimmune Holdings  (LSE:ONC) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Oncimmune Holdings Net Margin % Related Terms

Thank you for viewing the detailed overview of Oncimmune Holdings's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncimmune Holdings (LSE:ONC) Business Description

Traded in Other Exchanges
Address
1 Park Row, MediCity - D6 Building, Leeds, GBR, LS1 5AB
Oncimmune Holdings PLC is engaged in diagnosing cancer. It is involved in the development, manufacture, and commercialization of personalized immunodiagnostics for the screening, detection and care of cancer. The company's operating segment includes Early CDT Lung and ImmunoINSIGHTS.

Oncimmune Holdings (LSE:ONC) Headlines

No Headlines